Advance in the Treatment of Pediatric Leukemia

• Andere auteurs: Handgretinger, Rupert (Redacteur)
• Formaat: Elektronisch Hoofdstuk
• Taal: Engels
• Gepubliceerd in: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
• Onderwerpen: Research & information: general; Chemistry; acute lymphoblastic leukemia; pediatric; advances; diagnosis; treatment; immunotherapy; bispecific T-cell engager (BiTE); BCP-ALL; leukemia; TRAIL; antibody; Fc-engineering; xenograft; CD19; juvenile myelomonocytic leukemia; RAS signaling; hematopoietic stem cell transplantation; 5-azacitidine; myelodysplastic/myeloproliferative disorders; targeted therapy; ADC; antibody-drug conjugate; pediatric leukemia; ALL; AML; allogeneic stem cell transplantation; acute myeloid leukemia; minimal residual disease; conditioning regimen; alternative donors; B-ALL; DUX4; IKZF1; PAX5; Ph-like; ZNF384; NUTM1; T-ALL; NOTCH1; BCL11B; transcriptome; genome; chronic myeloid leukemia; CML; tyrosine kinase inhibitor; immunizations; COVID-19; childhood acute lymphoblastic leukemia; low-risk ALL; risk-stratified treatment; treatment related toxicity; L-asparaginase; acute pancreatitis; polymorphism; SNV; ABCC4; CFTR; other extramedullary relapse; lymphoblastic leukemia; children; prognosis; evolution of CAR T cells; FDA-approved CAR products; TcR versus CAR; limitations and complications of CAR T cell therapy; future directions of CAR T cell therapy; n/a
• Online toegang: DOAB: download the publication; DOAB: description of the publication

The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are di...